Advertisement

Topics

Recombinant Virus Vectors for the Treatment of Glycogen Storage Disease type Ib (GSD-Ib)

20:00 EDT 14 May 2019 | NIH

Glycogen storage disease type Ib (GSD-Ib) is an autosomal recessive disorder caused by deficiencies in glucose-6-phosphate transporter (G6PT), a ubiquitously expressed endoplasmic reticulum (ER) protein that translocates G6P from the cytoplasm into the ER lumen.  Inside the ER, G6P is hydrolyzed to glucose and phosphate by either the liver/kidney/intestine-restricted glucose-6-phosphatase-α (G6Pase-α or G6PC) or the ubiquitously expressed G6Pase-β.  G6PT and G6Pase are functionally co-dependent and form the G6PT/G6Pase complexes. The G6PT/G6Pase-α complex maintains interprandial blood glucose homeostasis, while the G6PT/G6Pase-β complex maintains neutrophil/macrophage homeostasis and function. Therefore, GSD-Ib is not only a metabolic – but also an immune disorder – characterized by impaired glucose homeostasis, neutropenia, and myeloid dysfunction.  

Allowing GSD-Ib to go untreated in juveniles can lead to metabolic and immune abnormalities – including fasting hypoglycemia and frequent infections. In severe cases it can be deadly. Currently, treatments include strict dietary therapies coupled with granulocyte colony stimulating factor therapy. However, these therapies fail to address several possible long-term complications – such as hepatocellular adenoma, which develops in 75% of GSD-I patients over 25 years-old.

This invention consists of two novel gene therapy vectors for the treatment of GSD-Ib that include recombinant nucleic acid molecules having a human G6PT coding sequence operably linked to either a human G6PC promoter/enhancer (GPE) sequence, or a minimal G6PT promoter/enhancer (miGT) sequence, respectively. Both have shown capable of protecting against age-related insulin resistance and obesity. These vectors are available for licensing and/or co-development: The qualified license applicant will have a capability to arrange: (i) the conduct of preclinical research, (ii) regulatory submissions to the FDA, (iii) clinical testing, and (iv) commercial manufacturing related to the development of a therapy for GSD1b.

IC: 
NICHD
NIH Ref. No.: 
E-072-2017
Advantages: 
  • The invention offers the first opportunity to treat GSD-Ib by gene therapy; they are anticipated to be the most efficacious therapy and will offer patients a chance to live a relatively normal life
  • Liver-directed gene transfer and expression corrects metabolic abnormalities and prevents hepatocellular adenoma (HCA) development with low potential safety concerns
  • These vectors have shown capable of protecting against age-related insulin resistance and obesity
  • Gene therapy approach might prevent long-term complications arising due to recurrent hypoglycemia and related biochemical abnormalities
Applications: 
  • Gene therapy for GSD-Ib 
  • Hepatocellular adenoma
  • Rare, pediatric metabolic disease
Development Status: 

Pre-clinical (in vivo)

Updated On: 
May 15, 2019
Date Published: 
Wednesday, May 15, 2019
Provider Classifications: 
Publications: 
Patent Application: 
62/451,963
PCT/US2018/015957
Licensing Contacts: 
Lead Inventor: 
Inventor IC: 
NICHD
Inventor Lab URL: 
https://irp.nih.gov/pi/janice-chou
LPM FIrst Name: 
John
LPM Last Name: 
Hewes
Inv Is lead: 
LPM Phone: 
240-276-5515
LPM Suffix: 
Ph.D.
LPM Organization: 
NCI - National Cancer Institute
DTDT Classification: 
Therapeutics
DTDT Description: 
Therapeutics
Pat Filing Date: 
2017-01-30
2018-01-30
Publication Link: 
https://www.ncbi.nlm.nih.gov/pubmed/19376605
https://www.ncbi.nlm.nih.gov/pubmed/20389290
Publication Caption: 
19376605
20389290
Publication Title: 

Yiu WH, et. al. Normoglycemia alone is insufficient to prevent long-term complications of hepatocellular adenoma in glycogen storage disease type Ib mice 

Yiu WH, et. al. Complete Normalization of Hepatic G6PC Deficiency in Murine Glycogen Storage
Disease Type Ia Using Gene Therapy 

Collaboration Sought: 
Yes
Institute or Center: 
Collaboration Opportunity: 

Licensing and research collaboration

E Number Only: 
E-072-2017
Inventor First Name: 
Janice
Inventor Last Name: 
Chou

Original Article: Recombinant Virus Vectors for the Treatment of Glycogen Storage Disease type Ib (GSD-Ib)

NEXT ARTICLE

More From BioPortfolio on "Recombinant Virus Vectors for the Treatment of Glycogen Storage Disease type Ib (GSD-Ib)"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...

Hepatology
Hepatology is the study of liver, gallbladder, biliary tree, and pancreas, and diseases associated with them. This includes viral hepatitis, alcohol damage, cirrhosis and cancer. As modern lifestyles change, with alcoholism and cancer becoming more promi...